- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03638375
TIL and Anti-PD1 in Metastatic Melanoma (ACTME)
Adoptive TIL Therapy With Low-dose IFN-alpha Plus Anti-PD1 in Metastatic Melanoma
Study Overview
Status
Intervention / Treatment
Detailed Description
The ACTME is an investigator initiated, single center phase I/II clinical trial for patients with progressive unresectable stage III or stage IV melanoma.
Patients are conditioned by low-dose IFN-alpha and treated with ACT and PD-1 antibodies. With this approach the investigators hope to solve 4 of the most important aspects curtailing the efficacy of current immunotherapies in metastatic melanoma:
- the lack of sufficient numbers of activated tumor-reactive T cells in patients by providing ACT; and
- the inhibition of T-cell effector function through PD-1 signalling by administration of nivolumab; as well as
- the toxicity of high-dose IL-2, and
- long term hospitalization of patients due to the conditioning-regimen used in most ACT protocols by replacing it with low-dose IFN-alpha treatment.
The trial consists of both a phase I part to determine safety and feasibility and a phase II part to evaluate first clinical activity of IFN-alpha, nivolumab and TIL.
The treatment with IFN-alpha will be added after the combination of TIL and nivolumab has proven to be safe in the first cohort of the phase I part of the trial.
Study Type
Enrollment (Estimated)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Contact
- Name: Ellen Kapiteijn, Dr.
- Phone Number: 071 526 9111
- Email: H.W.kapiteijn@lumc.nl
Study Contact Backup
- Name: Monique K. van der Kooij, Drs.
- Phone Number: 071 526 9111
- Email: m.k.van_der_kooij@lumc.nl
Study Locations
-
-
-
Leiden, Netherlands, 2333 ZA
- Leiden University Medical Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Age ≥ 18 years
- Histologically or cytologically proven metastatic skin melanoma
Melanoma must be at one of the following AJCC 2009 stages:
- Unresectable (or residual) regional metastatic melanoma, i.e. in terms of AJCC 2009 classification unresectable stage III melanoma, or
- Stage IV melanoma, i.e. distant metastatic disease (any T, any N, M1a, M1b or M1c), and normal LDH
- Patients have failed on standard treatment options
- Patients with brain metastases have to be neurologically stable for at least 2 months and should not use dexamethasone
- Presence of measurable progressive disease according to RECIST version 1.1
- Expected survival of at least 3 months
- WHO performance status ≤1
Within the last 2 weeks prior to study day 1, vital laboratory parameters should be within normal range, except for the following laboratory parameters, which should be within the ranges specified:
Lab Parameter Range Hemoglobin ≥ 6,0 mmol/l Granulocytes ≥ 1,500/µl Lymphocytes ≥ 700/µl Platelets ≥ 100,000/µl Creatinine clearance ≥ 60 min/ml Serum bilirubin ≤ 40 µmol/l ASAT and ALAT ≤ 5 x the normal upper limit LDH ≤ 2 x the normal upper limit
Viral tests must be performed at least 30 days before surgery:
- Negative for HIV type 1/2, HTLV and TPHA
- No HBV (hepatitis B virus) antigen or antibodies against HBc in the serum
- No antibodies against HCV (hepatitis C virus) in the serum
- Able and willing to give valid written informed consent.
- Progressive disease on prior treatment with f.e. BRAF-inhibitors, MEK-inhibitors or immunotherapy, including anti-PD1 treatment. Systemic therapy must have been discontinued for at least four weeks before start of study treatment.
Exclusion Criteria:
- Patients with brain metastases who are neurologically unstable and/or use dexamethasone
- Clinically significant heart disease (NYHA Class III or IV)
- Other serious acute or chronic illnesses, e.g. active infections requiring antibiotics, bleeding disorders, or other conditions requiring concurrent medications not allowed during this study
- Active immunodeficiency disease, autoimmune disease requiring immune suppressive drugs or autoimmune adverse events following treatment with checkpoint inhibitors. Vitiligo is not an exclusion criterion
- Subjects with a condition requiring systemic chronic steroid therapy (≥ 10mg/day prednisone or equivalent) or any immunosuppressive therapy within 14 days prior to planned date for first dose of study treatment. Topical, inhaled, nasal and ophthalmic steroids, and adrenal replacement therapy are allowed.
- Other malignancy within 2 years prior to entry into the study, except for treated non-melanoma skin cancer and in situ cervical carcinoma
- Mental impairment that may compromise the ability to give informed consent and comply with the requirements of the study
- Any serious or uncontrolled medical disorder or active infection that, in the opinion of the investigator, may increase the associated with the participation, study drug administration, or would impair the ability of the patient to receive protocol therapy
- Lack of availability for follow-up assessments
- Pregnancy or breastfeeding
- Known allergy to penicillin or streptomycin (used during the culturing of T cells)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Sequential Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Treatment with nivolumab plus TIL
In the first cohort the subcutaneous IFN-alpha injections will be omitted and the combination of nivolumab and TIL is given.
|
During 15 weeks patients will be treated with nivolumab (3mg/kg i.v.) once every two weeks. Four weeks after starting nivolumab, patients will receive their first TIL infusion (2.5-7.5x10^8 T cells i.v.) once every three weeks for three infusions. In the second group treatment with IFN-alpha (3 million IU s.c.) daily will be added one week before the first TIL infusion and will be continued for 11 weeks. |
Experimental: Treatment with Nivolumab plus TIL and IFN-alpha
In the second cohort of the first phase and the second phase of the trial patients will be treated with subcutaneous IFN-alpha injections in combination with TIL and nivolumab.
|
During 15 weeks patients will be treated with nivolumab (3mg/kg i.v.) once every two weeks. Four weeks after starting nivolumab, patients will receive their first TIL infusion (2.5-7.5x10^8 T cells i.v.) once every three weeks for three infusions. In the second group treatment with IFN-alpha (3 million IU s.c.) daily will be added one week before the first TIL infusion and will be continued for 11 weeks. |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence of treatment-related serious adverse events as assessed by CTCAE 4.0 criteria
Time Frame: 14 weeks after start of treatment
|
To evaluate the safety and toxicity of ACT with nivolumab, followed by evaluating the safety and toxicity of IFN-alpha, and nivolumab plus ACT according to the common terminology criteria of adverse events (CTCAE) 4.0 criteria. Treatment related adverse events grade 3 or less and SAE related to treatment that do not result in treatment termination are considered acceptable for continuation of the study.
|
14 weeks after start of treatment
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Evaluation of disease control rate according to RECIST 1.1 criteria
Time Frame: 14 weeks after first nivolumab infusion
|
Disease control is defined by complete response, partial response or stable according to RECIST 1.1 versus no clinical benefit defined as progressive disease. Complete response: Disappearance of all target and nontarget lesions, nodes must regress to <10mm short axis, no new lesions, confirmation required Partial response: ≥30% decrease in tumor burden compared with baseline, confirmation required Progressive disease: ≥20% + 5 mm absolute increase in tumor burden compared with nadir, appearance of new lesions or progression of nontarget lesions Stable disease: neither partial response nor progressive disease |
14 weeks after first nivolumab infusion
|
Evaluation of disease control rate according to immune RECIST response criteria
Time Frame: 14 weeks after first nivolumab infusion
|
Disease control is defined by complete response, partial response or stable according to the iRECIST versus no clinical benefit defined as progressive disease. Complete response: Disappearance of all lesions Partial response: ≥30% decrease in tumor burden compared with baseline. Progressive disease: ≥20% + 5 mm absolute increase in tumor burden compared with nadir Stable disease: neither progressive disease nor partial response |
14 weeks after first nivolumab infusion
|
To study the potential working mechanisms of the different treatment compounds. Therefore, blood will be drawn to analyse changes in circulating immune cells and their function during treatment.
Time Frame: Within 5 years after first inclusion
|
The investigators will analyse the patients their tumor material, blood, serum and the TILs used for infusion
|
Within 5 years after first inclusion
|
To establish a possible prognostic biomarker profile in patients tumor material, blood, serum and TILs used for infusion
Time Frame: Within 5 years after first inclusion
|
The investigators will analyse the patients their tumor material, blood, serum and the TILs used for infusion to look at changes in the number and phenotype of circulating immune cells, the cytokines that are produced by these cells and serum/plasma markers of persistence.
|
Within 5 years after first inclusion
|
To characterize the infusion product
Time Frame: Within 5 years after first inclusion
|
The expression of co-inhibitory molecules on T cells and regulatory T cells will be measured by flow cytometry.
Furthermore, the investigators will assess the fraction of tumor-specific TIL, their cytolytic capacity as well as to analyse their persistence in the circulation.
The supernatants of T cell are used for cytokine analysis assays.
|
Within 5 years after first inclusion
|
To analyse potential correlations between the clinical response and hypothesis related immune parameters
Time Frame: Within 5 years after first inclusion
|
Within 5 years after first inclusion
|
|
To analyse the overall survival following treatment
Time Frame: Within 5 years after first inclusion
|
The overall survival of all patients entering the study will be monitored
|
Within 5 years after first inclusion
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Ellen Kapiteijn, Dr., LUMC
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Chemically-Induced Disorders
- Neoplasms by Histologic Type
- Neoplasms
- Neuroectodermal Tumors
- Neoplasms, Germ Cell and Embryonal
- Neoplasms, Nerve Tissue
- Neuroendocrine Tumors
- Nevi and Melanomas
- Melanoma
- Drug-Related Side Effects and Adverse Reactions
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Antiviral Agents
- Antineoplastic Agents
- Immunologic Factors
- Antineoplastic Agents, Immunological
- Immune Checkpoint Inhibitors
- Interferons
- Interferon-alpha
- Nivolumab
Other Study ID Numbers
- NL64805.000.18
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Effects of Immunotherapy
-
Shanghai Juncell TherapeuticsSir Run Run Shaw HospitalRecruitingAdvanced Solid Tumor | Treatment Side Effects | Effects of Immunotherapy | Tumor Infiltrating LymphocytesChina
-
Philippe BéginThe Hospital for Sick Children; Centre de recherche du Centre hospitalier universitaire... and other collaboratorsRecruitingImmunotherapy | Physiological Effects of Drugs | Food IgE-mediated Allergy | OmalizumabCanada
-
Shanghai Juncell TherapeuticsShanghai 10th People's HospitalRecruitingBreast Cancer | Advanced Breast Cancer | Treatment Side Effects | Effects of ImmunotherapyChina
-
Aalborg UniversityCompletedQuality of Life | Hypersensitivity | Asthma | Effects of Immunotherapy | Rhino-Conjunctivitis
-
RadiotherapieCompletedMelanoma | Effects of Immunotherapy | Adverse Effect of Radiation TherapyBelgium
-
Michael von WolffUniversity of BernNot yet recruitingCancer | Fertility Issues | Effects of Immunotherapy | Toxicity Due to Chemotherapy | Toxicity Due to Radiotherapy | Fertility Preservation
-
University Hospital, GrenobleInstitut National de la Santé Et de la Recherche Médicale, France; Etablissement... and other collaboratorsCompletedMelanoma | Effects of Immunotherapy | Tumor VaccinesFrance
-
Shanghai Juncell TherapeuticsShanghai 10th People's HospitalRecruitingTreatment Side Effects | Effects of Immunotherapy | Advanced Liver Cancers | Tumor Infiltrating Lymphocyte | Advanced Pancreatic CancersChina
-
Shanghai Juncell TherapeuticsShanghai 10th People's HospitalRecruitingTreatment Side Effects | Effects of Immunotherapy | Advanced Melanoma | Tumor Infiltrating LymphocyteChina
-
Shanghai Juncell TherapeuticsShanghai 10th People's HospitalRecruitingAdvanced Gynecologic Tumors | Treatment Side Effects | Effects of Immunotherapy | TIL Engineered With Membrane-Binding CytokineChina
Clinical Trials on Nivolumab & Tumor Infiltrating Lymphocytes with/without Interferon-Alpha
-
H. Lee Moffitt Cancer Center and Research InstituteUnited States Department of DefenseRecruitingUrothelial Carcinoma | Non-Invasive Bladder Urothelial CarcinomaUnited States
-
Iovance Biotherapeutics, Inc.RecruitingSquamous Cell Carcinoma of the Head and Neck | Metastatic Melanoma | Non-small Cell Lung CancerUnited States, Spain, Canada, France, Germany, Greece, Switzerland, United Kingdom
-
Leiden University Medical CenterRecruitingOvarian Cancer RecurrentNetherlands
-
Yale UniversityTerminatedMetastatic MelanomaUnited States
-
H. Lee Moffitt Cancer Center and Research InstituteRecruitingNon Small Cell Lung Cancer | Stage IV Non-small Cell Lung Cancer | Recurrent Non Small Cell Lung CancerUnited States
-
H. Lee Moffitt Cancer Center and Research InstituteBristol-Myers Squibb; Stand Up To Cancer; Iovance Biotherapeutics, Inc.; Prometheus...CompletedNon-Small Cell Lung Cancer | Adenocarcinomas | Squamous Cell Carcinoma | Advanced NSCLC | Metastatic Non-small Cell Lung Cancer | Adenosquamous CarcinomaUnited States
-
Hoag Memorial Hospital PresbyterianCompletedKidney Cancer | Unspecified Adult Solid Tumor, Protocol Specific | Melanoma (Skin)United States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI); Iovance Biotherapeutics, Inc.Active, not recruitingMalignant Solid Neoplasm | Soft Tissue Sarcoma | Recurrent Ovarian Carcinoma | Triple Negative Breast Cancer | Recurrent Osteosarcoma | Refractory Osteosarcoma | Bone Sarcoma | Giant Cell Tumor of Bone | Ovarian Carcinosarcoma | Platinum-Resistant Ovarian Carcinoma | Dedifferentiated Chondrosarcoma | Malignancy... and other conditionsUnited States
-
Inge Marie SvaneRecruitingPeritoneal Cancer | Metastatic Ovarian Cancer | Metastatic Fallopian Tube CancerDenmark
-
University of Maryland, BaltimoreUniversity of Maryland Greenebaum Cancer CenterCompletedInfection | Multiple Myeloma and Plasma Cell NeoplasmUnited States